Identification of Biomarkers of Attention Deficit Disorder With or Without Hyperactivity (ADHD) by a Metabolomic Approach in Children
Overview
- Phase
- N/A
- Intervention
- Not specified
- Conditions
- Adhd
- Sponsor
- University Hospital, Tours
- Enrollment
- 89
- Locations
- 1
- Primary Endpoint
- ADHD metabolomic's signature of blood
- Status
- Completed
- Last Updated
- 4 years ago
Overview
Brief Summary
Attention-deficit with or without hyperactivity disorder (ADHD) is a real health public concern. No easy-use diagnosis tool are available. Metabolomic approaches has brought very usefull data in others neurological diseases like amyotrophic lateral sclerosis or autism spectrum disorder, as we had shown in previous studies. Targeting on neurotransmitter pathways involving in ADHD, metabolomic screening could help to enhance our diagnosis power to better help numerus of children. We propose to study the phenylalanine and the tyrosine pathways with a multimodal metabolomic approach, in easy-available biological fluid (blood and urine), in child or adolescent suspected of ADHD. Our objectives are: 1- to determine a specific metabolomic signature of ADHD 2- to compare the diagnostic value of this metabolomic signature with the reference methodology for ADHD diagnosis, as now practiced in our reference center for learning troubles.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Child or adolescent with symptoms of attention disorders and / or hyperactivity
- •aged from 6 to 15 years old
Exclusion Criteria
- •Failure or refusal of all or part of the multidisciplinary evaluation (medical and / or neuropsychological assessments and / or biological assessments)
- •Identification of an intercurrent condition likely to have an impact on metabolomic analyzes (acute infection, fever, etc.)
- •Parents or legal guardians opposed to data processing
Outcomes
Primary Outcomes
ADHD metabolomic's signature of blood
Time Frame: At baseline
Detection of metabolites (phenylalanine or catécholamines) in the blood of patients with ADHD at levels significantly different from baseline levels in the general population and rates found in patients with attention deficit and / or hyperactivity disorders but that multidisciplinary assessment excludes the diagnosis of ADHD.
ADHD metabolomic's signature of urine
Time Frame: At baseline
Detection of metabolites (phenylalanine or catécholamines) in the urine of patients with ADHD at levels significantly different from baseline levels in the general population and rates found in patients with attention deficit and / or hyperactivity disorders but that multidisciplinary assessment excludes the diagnosis of ADHD.